Targeting the CDK9 pathway, which is dysregulated in AML, is an attractive approach leading to downregulation of genes regulated by super enhancers such as MCL1, MYC and cyclin D1 [reviewed in 3]. The gene discussed is MCL1; the disease is acute myeloid leukemia.